ArticleJournal of clinical microbiology2002
Qualitative detection of hepatitis C virus RNA: comparison of analytical sensitivity, clinical performance, and workflow of the Cobas Amplicor HCV test version 2.0 and the HCV RNA transcription-mediated amplification qualitative assay.
Article in Journal of clinical microbiology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 52 citations in OpenAlex.
- Inhibition of Non-specific Amplification in Loop-Mediated Isothermal Amplification via Tetramethylammonium Chloride.Biochip journal · 2022Article
- Simultaneous determination of HCV genotype and NS5B resistance associated substitutions using dried serum spots from São Paulo state, Brazil.Access microbiology · 2022Article
- Introduction of an automated system for the diagnosis and quantification of hepatitis B and hepatitis C viruses.The open virology journal · 2012Article
- Assessment of Aspergillus fumigatus in guinea pig bronchoalveolar lavages and pulmonary tissue by culture and realtime polymerase chain reaction studies.International journal of molecular sciences · 2012Article
- Evaluation of operational chronic infection endpoints for HCV vaccine trials.Contemporary clinical trials · 2008Article
- [Diagnostics and therapy of chronic hepatitis B and C].Der Internist · 2008Review
- Ultracentrifugation of serum samples allows detection of hepatitis C virus RNA in patients with occult hepatitis C.Journal of virology · 2007Article
- Transcription-mediated amplification linked to line probe assay as a routine tool for HCV typing in clinical laboratories.Journal of clinical laboratory analysis · 2007Article
- Hepatitis C infection in dialysis patients: a link to poor clinical outcome?International urology and nephrology · 2007Review
- Evaluation of the core antigen assay as a second-line supplemental test for diagnosis of active hepatitis C virus infection.Journal of clinical microbiology · 2004Article
- Performance characteristics of a quantitative TaqMan hepatitis C virus RNA analyte-specific reagent.Journal of clinical microbiology · 2004Article
- Increased sensitivity of the Roche COBAS AMPLICOR HCV test, version 2.0, using modified extraction techniques.The Journal of molecular diagnostics : JMD · 2004Article
- Evaluation of the MagNA pure LC instrument for extraction of hepatitis C virus RNA for the COBAS AMPLICOR Hepatitis C Virus Test, version 2.0.Journal of clinical microbiology · 2003Article
- Multicenter evaluation of the VERSANT HCV RNA qualitative assay for detection of hepatitis C virus RNA.Journal of clinical microbiology · 2003Article
- Performance evaluation of the VERSANT HCV RNA qualitative assay by using transcription-mediated amplification.Journal of clinical microbiology · 2003Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The qualitative Cobas Amplicor hepatitis C virus (HCV) version 2.0 assay (HCV PCR) and the Bayer Reference Testing Laboratory HCV RNA transcription-mediated amplification assay (HCV TMA) were compared for analytical sensitivity, clinical performance, and workflow. Limits of detection were determined by testing dilutions of the World Health Organization HCV standard in replicates of 15 at concentrations of from 1.0 to 70 IU/ml. The limit of detection of the HCV PCR assay was calculated to be 45 IU/ml on initial testing and 32 IU/ml after resolution of gray zone results. The calculated limit of detection for HCV TMA was 6 IU/ml. To compare clinical performance, 300 specimens, grouped as follows, were evaluated: 112 samples that were indeterminate in an anti-HCV enzyme immunoassay (EIA) and for which HCV RNA was not detected by HCV PCR; 79 samples that were EIA positive and for which HCV RNA was not detected by HCV PCR; and 105 samples that were both EIA and HCV PCR positive. For these groups, interassay concordance ranged from 96.2% to 100%. In addition, three HCV PCR gray zone specimens and one neonatal specimen were also evaluated. A 64-sample run (full run, 91 specimens) required 5 h for testing by HCV TMA, whereas almost 8 h were required to test a full run of 22 specimens by HCV PCR. HCV TMA demonstrated excellent concordance with HCV PCR when clinical samples were tested. However, HCV TMA was more sensitive than HCV PCR, required less time for test result completion, and had a greater throughput.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.